Concepedia

Meisa Wang

MW

5

Publications

132

Citations

5

H-Index

2017

Active since

Affiliations

China Pharmaceutical University(Current)

First Affiliated Hospital of Xinjiang Medical University

Tianjin Medical University Cancer Institute and Hospital

Xinjiang Medical University

Meisa Wang is an author at China Pharmaceutical University specializing in lung cancer, cell death, and cancer research.

Top concepts

Publications per year

2017–2022

5

Publications

5

BHX, a novel pyrazoline derivative, inhibits breast cancer cell invasion by reversing the epithelial-mesenchymal transition and down-regulating Wnt/β-catenin signalling

Hanmei Bao, Qing Zhang, Zhongling Zhu et al. · Scientific Reports · 2017 · 32 citations · Full text

PPARα agonist fenofibrate relieves acquired resistance to gefitinib in non-small cell lung cancer by promoting apoptosis via PPARα/AMPK/AKT/FoxO1 pathway

Meisa Wang, Qiushuang Han, Zhirong Jia et al. · Acta Pharmacologica Sinica · 2021 · 31 citations · Full text

, , +9

Silk fibroin peptide suppresses proliferation and induces apoptosis and cell cycle arrest in human lung cancer cells

Meisa Wang, Yibo Du, Huiming Huang et al. · Acta Pharmacologica Sinica · 2018 · 29 citations · Full text

, , +14

1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells

Zhirong Jia, Yameng Zhang, Aiwen Yan et al. · Cell Death and Disease · 2020 · 29 citations · Full text

Claudin1 decrease induced by 1,25-dihydroxy-vitamin D3 potentiates gefitinib resistance therapy through inhibiting AKT activation-mediated cancer stem-like properties in NSCLC cells

Zhirong Jia, Kaiwei Wang, Yalei Duan et al. · Cell Death Discovery · 2022 · 11 citations · Full text

Rows per page

1–5 of 5